Prostate Cancer: High Dose Calcitrol plus Docetaxel reduces PSA by gre

The Oregon Health and Science University in treating late stage prostate cancer patients with a promising combination, calcitrol, (the active form of Vitamin D) and decetoxel. In a pilot study reported at a recent ASCO meeting, 81% of patients had a PSA decrease of greater than 50%. Keep checking back as we update you on this exciting treatment protocol

Webmaster

November 28, 2002